Radiation-guided drug delivery to mouse models of lung cancer

Clinical Cancer Research

Volumn 16, Issue 20, 2010, Pages 4968-4977

  Hariri, Ghazal ^a   Yan, Heping ^b   Wang, Hailun ^a   Han, Zhaozhong ^a   Hallahan, Dennis E ^b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Washington University in St Louis School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; PACLITAXEL; RECOMBINANT HORMONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOAVAILABILITY; CANCER CHEMOTHERAPY; CANCER INHIBITION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG SPECIFICITY; IRRADIATION; LEWIS CARCINOMA; LUNG CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION; RADIATION DOSE; RADIOSENSITIZATION; SINGLE DRUG DOSE; THERAPY EFFECT; TUMOR VASCULARIZATION;

ALBUMINS; AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL AVAILABILITY; CARCINOMA, LARGE CELL; CARCINOMA, LEWIS LUNG; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GUINEA PIGS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, NUDE; MOLECULAR SEQUENCE DATA; PACLITAXEL; PEPTIDES; RABBITS; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77958061484     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-0969     Document Type: Article

References (39)

1. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998;279:377-80. (Pubitemid 28063372)
2. Sengupta S, Eavarone D, Capila I, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature Letters 2005;436:568-72.
3. Karmali PP, Kotamraju V, Kastantin M, et al. Targeting of albumin-embedded paclitaxel nanoparticles to tumors. Nanomedicine 2009;5:73-82.
4. Desai N, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res 2006;12:1317-24.
5. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004;303:1818-22.
6. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology 2007;2:751-60.
7. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nature Reviews 2008;7:771-82.
8. Foote M. Using nanotechnology to improve the characteristics of antineoplastic drugs: improved characteristics of nab-paclitaxel compared with solvent-based paclitaxel. Biotechnol Annu Rev 2007;13:345-57.
9. Hawkins MJ, Soon-shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008;60:876-85.
10. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008;132:171-83, doi:10.1016/j.jconrel. 2008.05.010.
11. Vogel SM, Minshall RD, Pilipovic M, Tiruppathi C, Malik AB. Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiology 2001;281:L1512-22.
12. Tiruppathi C, Song W, Bergenfeldt M, Sass P, Malik AB. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J Biol Chem 1997;272:25968-75.
13. Minshall RD, Tiruppathi C, Vogel SM, et al. Endothelial cell-surface gp60 activates vesicle formation and trafficking via G(i)-coupled Src kinase signaling pathway. J Cell Biol 2000;150:1057-70.
14. John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol 2003;284:L187-96.
15. Damascelli B, Patelli GL, Lanocita R, et al. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: preliminary findings. AJR Am J Roentgenol 2003;181:253-60.
16. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794-803.
17. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006;17:1263-8.
18. Lee T, Lin C, Kuo S, Chang D, Wu H. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res 2007;67:10958-65.
19. Hallahan DE, Geng L, Qu S, et al. Integrin-mediated targeting of drug delivery to irradiated tumor blood vessels. Cancer Cell 2003;3:63-74. (Pubitemid 37443891)
20. Hallahan DE, Qu S, Geng L, et al. Radiation-mediated control of drug delivery. Am J Clin Oncol 2001;24:473-80.
21. Hariri G, Zhang Y, Fu A, et al. Radiation-guided P-selectin antibody targeted to cancer. Ann Biomed Eng 2008;36:821-30.
22. Pattilo CB, Venegas B, Donelson FJ, et al. Radiation-guided targeting of combretastatin encapsulated immunoliposomes to mammary tumours. Pharm Res 2009;26:1093-100.
23. Passarella RJ, Spratt DE, van der Ende AE, et al. Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors. Cancer Res 2010;70:4550-9.
24. Han Z, Fu A, Wang H, et al. Noninvasive assessment of cancer response to therapy. Nat Med 2008;14:343-9.
25. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996;380:364-6.
26. Geng L, Osusky K, Konjeti S, Fu A, Hallahan DE. Radiation-guided drug delivery to tumor blood vessels results in improved tumor growth delay. J Control Release 2004;99:369-81.
27. Dillman RO, Herndon J, Seagren SL, Eaton WL, Jr., Green MR. Improved survival in stage III non-small cell lung cancer: seven year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996;88:1210-5.
28. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005;23:5883-91.
29. Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs. concurrent chemoradiation for patients with unresected stage III non-small cell lung cancer. RTOG 9410. Proceedings of the American Society of Clinical Oncology 2003;22:621a.
30. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005;23:5910-7.
31. Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 1999;17:2692-9.
32. Gardner ER, Dahut W, Figg WD. Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment. J Chromatogr B Analyt Technol Biomed Life Sci 2008;862:213-8.
33. Wiedenmann N, Valdecanas D, Hunter N, et al. 130-nm albumin-bound paclitaxel enhances tumor radiocurability and therapeutic gain. Clin Cancer Res 2007;13:1868-74.
34. Kruskal WH, Wallis WA. Use of ranks in one-criteria variance analysis. J Am Stat Assoc 1952;47:583-621.
35. Hong JW, Lee IH, Kwak YH, et al. Efficacy and tissue distribution of DHP107, an oral paclitaxel formulation. Mol Cancer Ther 2007;6:3239-47.
36. Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol 2005;23:1137-46.
37. Milenic DE, Brechbiel MW. Targeting of radio-isotopes for cancer therapy. Cancer Biol Ther 2004;3:361-70.
38. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010;146:264-75, doi:10.1016/j.jconrel.2010. 04.009.
39. Sugahara KN, Teesalu T, Karmali PP, et al. Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs. Science 2010;328:1031-5.